International journal of radiation oncology, biology, physics
-
Int. J. Radiat. Oncol. Biol. Phys. · Oct 2019
Comparative StudyElevated Risk of Radiation Therapy-Associated Second Malignant Neoplasms in Young African-American Women Survivors of Stage I-IIIA Breast Cancer.
To estimate the effect of radiation therapy (RT) on nonbreast second malignant neoplasms (SMNs) in young women survivors of stage I-IIIA breast cancer. ⋯ With a projected 25-year follow-up, RT is associated with elevated risk of nonbreast SMNs, particularly second lung cancer, in young women survivors of stage I-IIIA breast cancer. Nonbreast SMNs associated with RT are higher in AA women than Caucasian women.
-
Int. J. Radiat. Oncol. Biol. Phys. · Sep 2019
Taking Stock: The Canadian Association of Radiation Oncology 2017 Radiation Oncologist Workforce Study.
To identify and report radiation oncologist (RO) workforce demographics, clinical workload trends, and equipment inventory in Canada. ⋯ The Canadian RO workforce demonstrated incremental growth, but rising annual caseloads suggest that radiation therapy demand outpaced RO supply gains. Government funding is required to replace aging equipment in Canada.
-
Int. J. Radiat. Oncol. Biol. Phys. · Sep 2019
National Trends and Dynamic Responses in the Canadian Radiation Oncology Workforce From 1990 to 2018.
To report radiation oncology (RO) workforce and cancer incidence trends in Canada and explore the relationship between the two. ⋯ Our study demonstrates the challenges and successes of managing the Canadian radiation oncologist workforce. These data will inform policy makers and other stakeholders to ensure that the profession meets the current and future needs of Canadian cancer patients.
-
Int. J. Radiat. Oncol. Biol. Phys. · Aug 2019
Stereotactic Body Radiation Therapy Boost for Intermediate-Risk Prostate Cancer: A Phase 1 Dose-Escalation Study.
High-dose-rate brachytherapy boost plus external beam radiation therapy is an established option for intermediate-risk prostate cancer (PCa). Stereotactic body radiation therapy (SBRT) boost can potentially mimic high-dose-rate boost and could be a viable alternative. Here we report the long-term outcomes of a phase 1 dose-escalation trial of single-fraction SBRT boost. ⋯ Other than a grade 4 toxicity, which may in part be due to repeated biopsies of a rectal ulcer, single-fraction SBRT boost was feasible and well tolerated. Larger studies are warranted to better document the outcomes of such an approach.